Insider trade

CFO sold ~$184K of AMPH shares in the open market

Traded Aug 7, 2026 · Filed Aug 11, 2026

Why it stands out

The money chief of Amphstar Pharmaceuticals sold $184K of Amphstar Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CFO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$183,886

Shares × reported transaction price

Timing vs results

1 day after results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+8.8%	−0.4%	+9.3%
30 days	+19.0%	−1.1%	+20.1%

Past results only. Not a forecast.

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2026.

Automatic sale5w ago

Director sold

8w ago

A board member of Amphstar Pharmaceuticals sold $162K of Amphstar Pharmaceuticals shares. Nobody planned it ahead of time.

8w ago

Derivative exercise or conversion — not an open-market buy.